Loading
A phase 2 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Massachusetts General Hospital, now recruiting.
Sacituzumab Govitecan In TNBC. ClinicalTrials.gov record last updated 2026-07-17: recruiting. Enrollment is planned at 239 participants. Primary completion is estimated at 2028-10. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab Govitecan, Pembrolizumab. Registered primary measures: Pathological complete response(pCR) rate with sacituzumab govitecan.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab govitecan, TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC), Pembrolizumab and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC), Pembrolizumab and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/